Infos from the new Boehringer Ingelheim Research Report:
"To strengthen our research portfolio and expertise in developing NBEs binding to two targets (bispecific therapeutics), we have established partnerships with Ablynx NV, MacroGenics, Inc., and f-star Ges. m. b. H. Additionally, we work together with Micromet, Inc., (now part of Amgen) to develop and commercialise a BiTE® (bispecific T-cell engager) for the treatment of multiple myeloma."
Link:
http://discoveringtogether.boehringer-ingelheim.com/content/dam/internet/topical/discoveringtogether/com_EN/documents/Discovery_and_Development_Direct_01_2014.pdf
Anyone more infos about this development?
Forums
2 posts
• Page 1 of 1
Re: New "bispecific T-cell engager" (BiTE) antibody
I think there is a lot of research and investment going on with bi-specific antibodies for myeloma treatment, including heavyweights in the multiple myeloma industry like Celgene.
For those that don't know what this means, a monoclonal antibody (MAB) drug for myeloma is simply an antibody that is easily mass produced and can target a specific marker/flag (protein) that is somewhat unique to a cancer cell. You may have heard about MABS such as daratumumab that target the CD38 protein surface marker on multiple myeloma cells. The beauty of this approach is that only the cells that have this maker are targeted for intervention/destruction.
On the other hand, a bi-specific antibody can target a cancer cell that has TWO unique markers, making the drug even more targeted to a specific cancer cell (it's not like CD38 is ONLY found on a myeloma cancer cell). There are over 300 of these different markers on the surface of a cell that can be used to help distinguish a cancer cell from a healthy cell. More targeted deliveries of drugs is always a good thing ... less side effects and better efficacy. It's like the drug is saying to the myeloma cancer cell "we know who you are and we've got your address".
For those that don't know what this means, a monoclonal antibody (MAB) drug for myeloma is simply an antibody that is easily mass produced and can target a specific marker/flag (protein) that is somewhat unique to a cancer cell. You may have heard about MABS such as daratumumab that target the CD38 protein surface marker on multiple myeloma cells. The beauty of this approach is that only the cells that have this maker are targeted for intervention/destruction.
On the other hand, a bi-specific antibody can target a cancer cell that has TWO unique markers, making the drug even more targeted to a specific cancer cell (it's not like CD38 is ONLY found on a myeloma cancer cell). There are over 300 of these different markers on the surface of a cell that can be used to help distinguish a cancer cell from a healthy cell. More targeted deliveries of drugs is always a good thing ... less side effects and better efficacy. It's like the drug is saying to the myeloma cancer cell "we know who you are and we've got your address".
-
Multibilly - Name: Multibilly
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: Smoldering, Nov, 2012
2 posts
• Page 1 of 1